{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T10:57:47Z","timestamp":1774695467524,"version":"3.50.1"},"reference-count":23,"publisher":"Asia Pacific Academy of Ophthalmology","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia Pac J Ophthalmol (Phila)"],"published-print":{"date-parts":[[2019]]},"DOI":"10.22608\/apo.2018301","type":"journal-article","created":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T06:50:30Z","timestamp":1532501430000},"source":"Crossref","is-referenced-by-count":7,"title":["Treatment of Ocular Myasthenia Gravis"],"prefix":"10.22608","member":"9895","published-online":{"date-parts":[[2019]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/bjo.2004.063404","article-title":"Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment","volume":"89","author":"MJ","year":"2005","unstructured":"1. Kupersmith MJ, Ying G. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. Br J Ophthalmol. 2005;89:1330\u20131334.","journal-title":"Br J Ophthalmol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.24769","article-title":"Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized controlled trial","volume":"53","author":"Benatar","year":"2016","unstructured":"2. Benatar M, Mcdermott MP, Sanders DB, et al. Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized controlled trial. Muscle Nerve. 2016;53:363\u2013369.","journal-title":"Muscle Nerve"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/ene.12359","article-title":"EFNS\/ENS guidelines for the treatment of ocular myasthenia","volume":"21","author":"Kerty","year":"2014","unstructured":"3. Kerty E, Elsais A, Argov Z, et al. EFNS\/ENS guidelines for the treatment of ocular myasthenia. Eur J Neurol. 2014;21:687\u2013693.","journal-title":"Eur J Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1001\/archneur.1996.00550080128020","article-title":"Beneficial effects of corticosteroids on ocular myasthenia gravis","volume":"53","author":"Kupersmith","year":"1996","unstructured":"4. Kupersmith MJ, Moster M, Bhuiyan S, et al. Beneficial effects of corticosteroids on ocular myasthenia gravis. Arch Neurol. 1996;53:802\u2013804.","journal-title":"Arch Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/WNO.0b013e3182536558","article-title":"Safety of prednisone for ocular myasthenia gravis","volume":"32","author":"BB","year":"2012","unstructured":"5. Bruce BB, Kupersmith MJ. Safety of prednisone for ocular myasthenia gravis. J Neuroophthalmol. 2012;32:212\u2013215.","journal-title":"J Neuroophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1007\/s00415-009-5120-8","article-title":"Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up","volume":"256","author":"Kupersmith","year":"2009","unstructured":"6. Kupersmith MJ. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol. 2009;256:1314\u20131320.","journal-title":"J Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.ophtha.2015.03.010","article-title":"Prognosis of ocular myasthenia gravis: retrospective multicenter analysis","volume":"122","author":"Nagia","year":"2015","unstructured":"7. Nagia L, Lemos J, Abusamra K, et al. Prognosis of ocular myasthenia gravis: retrospective multicenter analysis. Ophthalmology. 2015;122:1517\u20131521.","journal-title":"Ophthalmology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/00207454.2017.1344237","article-title":"Factors affecting outcome in ocular myasthenia gravis","volume":"128","author":"Mazzoli","year":"2017","unstructured":"8. Mazzoli M, Ariatti A, Valzania F, et al. Factors affecting outcome in ocular myasthenia gravis. Int J Neurosci. 2017;128:15\u201324.","journal-title":"Int J Neurosci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/WNO.0000000000000270","article-title":"Does treatment of ocular myasthenia gravis with early immunosuppressive therapy prevent secondarily generalization and should it be offered to all such patients","volume":"36","author":"Wong","year":"2016","unstructured":"9. Wong SH, Plant G, Cornblath W. Does treatment of ocular myasthenia gravis with early immunosuppressive therapy prevent secondarily generalization and should it be offered to all such patients. J Neuroophthalmol. 2016;36:98\u2013102.","journal-title":"J Neuroophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00415-008-0718-9","article-title":"Mycophenolate mofetil for ocular myasthenia","volume":"255","author":"Chan","year":"2008","unstructured":"10. Chan CW. Mycophenolate mofetil for ocular myasthenia. J Neurol. 2008;255:510\u2013513.","journal-title":"J Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","article-title":"Ocular myasthenia gravis: response to long term immunosuppressive treatment","volume":"62","author":"Sommer","year":"1997","unstructured":"11. Sommer N, Sigg B, Melms A, et al. Ocular myasthenia gravis: response to long term immunosuppressive treatment. J Neurol Neurosurg Psychiatry. 1997;62:156\u2013162.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/14737175.2017.1241144","article-title":"Myasthenia gravis: recent advances in immunopathology and therapy","volume":"17","author":"JI","year":"2017","unstructured":"12. Lee JI, Jander S. Myasthenia gravis: recent advances in immunopathology and therapy. Expert Rev Neurother. 2017;17:287\u2013299.","journal-title":"Expert Rev Neurother"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial","volume":"68","author":"Zinman","year":"2007","unstructured":"13. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007;68:837\u2013841.","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","unstructured":"14. Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375:511\u2013522.","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13023-018-0837-z","article-title":"Thymectomy in nonthymomatous myasthenia gravis - systematic review and meta-analysis","volume":"13","author":"Cataneo","year":"2018","unstructured":"15. Cataneo AJM, Felisberto G Jr, Cataneo DC. Thymectomy in nonthymomatous myasthenia gravis - systematic review and meta-analysis. Orphanet J Rare Dis. 2018;13:99.","journal-title":"Orphanet J Rare Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s10072-017-3058-7","article-title":"Thymectomy is a beneficial therapy for patients with non-thymomatous ocular myasthenia gravis: a systematic review and meta-analysis","volume":"38","author":"Zhu","year":"2017","unstructured":"16. Zhu K, Li J, Huang X, et al. Thymectomy is a beneficial therapy for patients with non-thymomatous ocular myasthenia gravis: a systematic review and meta-analysis. Neurol Sci. 2017;38:1753\u20131760.","journal-title":"Neurol Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ncl.2018.01.003","article-title":"Ocular myasthenia","volume":"36","author":"Al-Haidar","year":"2018","unstructured":"17. Al-Haidar M, Benatar M, Kaminski HJ. Ocular myasthenia. Neurol Clin. 2018;36:241\u2013251.","journal-title":"Neurol Clin"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ncl.2016.08.008","article-title":"Update on ocular myasthenia gravis","volume":"35","author":"SV","year":"2017","unstructured":"18. Smith SV, Lee AG. Update on ocular myasthenia gravis. Neurol Clin. 2017;35:115\u2013123.","journal-title":"Neurol Clin"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"JF Jr","year":"2017","unstructured":"19. Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16:976\u2013986.","journal-title":"Lancet Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis","volume":"262","author":"Iorio","year":"2015","unstructured":"20. Iorio R, Damato V, Alboini PE, et al. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2015;262:1115\u20131119.","journal-title":"J Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1136\/bjophthalmol-2014-306335","article-title":"Blepharoptosis surgery in patients with myasthenia gravis","volume":"99","author":"Litwin","year":"2015","unstructured":"21. Litwin AS, Patel B, McNab AA, et al. Blepharoptosis surgery in patients with myasthenia gravis. Br J Ophthalmol. 2015;99:899\u2013902.","journal-title":"Br J Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/WNO.0b013e318280d630","article-title":"Long-term follow-up of strabismus surgery for patients with ocular myasthenia gravis","volume":"33","author":"Peragallo","year":"2013","unstructured":"22. Peragallo JH, Velez FG, Demer JL, et al. Long-term follow-up of strabismus surgery for patients with ocular myasthenia gravis. J Neuroophthalmol. 2013;33:40\u201344.","journal-title":"J Neuroophthalmol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/WNO.0000000000000611","article-title":"Rating scale for ocular myasthenia gravis: a call to action!","volume":"38","author":"Wong","year":"2018","unstructured":"23. Wong SH. Rating scale for ocular myasthenia gravis: a call to action! J Neuroophthalmol. 2018;38:138\u2013139.","journal-title":"J Neuroophthalmol","ISSN":"https:\/\/id.crossref.org\/issn\/1070-8022","issn-type":"print"}],"container-title":["Asia-Pacific Journal of Ophthalmology"],"original-title":[],"deposited":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T00:09:34Z","timestamp":1561766974000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/apjoo\/Fulltext\/2018\/07000\/Treatment_of_Ocular_Myasthenia_Gravis.8.aspx"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":23,"URL":"https:\/\/doi.org\/10.22608\/apo.2018301","relation":{},"ISSN":["2162-0989","2162-0989"],"issn-type":[{"value":"2162-0989","type":"print"},{"value":"2162-0989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}